/PRNewswire/ The gastrointestinal stromal tumors therapeutics market is anticipated to grow by USD 1.02 billion, progressing at a CAGR of 6.01% during the.
Gilead sinks after lung cancer drug fails to improve survival financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) Gilead Sciences Inc.’s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that’s in one of the most promising classes in oncology.Most Read from BloombergFlorida Governor DeSantis Drops Out of 2024 Race, Endorses TrumpHong Kong Stocks at 36% Discount Show True Depth of China GloomMorgan Stanley, JPMorgan Say Buy the Dip After Treasury RoutGloom Over China Assets Is Spreading Beyond Battered StocksHed
Esperion Is Sitting On A Potential Blockbuster Drug (NASDAQ:ESPR) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
While the value of partnerships and collaborations have climbed mostly upward in recent years, the most impressive increase has been seen with deals that are worth $1 billion or more – led in 2023 with a $22 billion antibody-drug conjugate pact between Daiichi Sankyo Co. Ltd. and Merck & Co. Inc.